Results 1 to 10 of about 17,963 (297)
Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study
Background Hyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after ...
Anna Sophia Posawetz+7 more
doaj +2 more sources
Background Recently, side effects from Dopamine Receptor Agonist Drugs (DAs) in treating pituitary prolactinoma have raised widespread concern. This study explores the incidence and influencing factors of DAs-related side effects in Chinese prolactinoma ...
Xiaoan Ke+7 more
doaj +2 more sources
Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway [PDF]
ObjectivesThis investigation sought to explore the inhibitory impact of wogonin on prolactinoma and elucidate its underlying mechanisms through network pharmacology, molecular docking (MD), and molecular biology experiments.MethodsTarget identification ...
Zhiyong Du+29 more
doaj +2 more sources
Inhibiting MAPK14 showed anti-prolactinoma effect
Background The specific underlying pathogenesis of prolactinoma has not been clarified yet, to the best of our knowledge. p38 mitogen-activated protein kinase (MAPK) signaling including p38α MAPK (MAPK14), p38β (MAPK11), p38γ (MAPK12) and p38δ (MAPK13 ...
Qiao-yan Ding+6 more
doaj +2 more sources
Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen+23 more
doaj +2 more sources
Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal.
Yunzhi Zou+6 more
doaj +2 more sources
Prolactinoma presenting as chronic anaemia with osteoporosis: a case report [PDF]
Introduction Unexplained anaemia is a rare mode of presentation for prolactinoma. We describe a case of a man, with chronic anaemia ascribed to old age.
Hanley John P, MacLean Fergus R
doaj +2 more sources
MicroRNA networks in prolactinoma tumorigenesis: a scoping review [PDF]
Background Prolactinoma is the leading type of pituitary adenoma. Aside from the mass-like effect of prolactinoma, its hormonal effect is the main pathological cause of endocrine dysregulation and infertility.
Sevil Ghaffarzadeh Rad+2 more
doaj +2 more sources
Objectives To investigate the expression levels of aromatase cytochrome P450 enzyme (P450AROM) and related molecules—estrogen receptor-beta (ER-β), Ki-67, and p53—in prolactinoma tumor tissue from pre- and post-menopausal women, and to determine the ...
Yin-Xia Su+9 more
doaj +2 more sources
Exploring retinal vessel density alterations in prolactinoma patients: Insights from OCTA imaging [PDF]
Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA). Design: A retrospective study.
Serife Ciloglu Hayat+3 more
doaj +2 more sources